Our Pricing

Wegovy In Stock: Private Prescriptions UK

Published on: June 03, 2026

Finding wegovy in stock uk private prescription services can be challenging during ongoing supply fluctuations. At Cured Pharmacy, we maintain reliable stock of genuine UK-licensed Wegovy (semaglutide) pens with transparent pricing from £79.00 supported by our UK-registered clinical team and superintendent pharmacist Tarun Kumar (GPhC 2233073). Your free online consultation takes under three minutes, with discreet next-day delivery available across the UK.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities [1]. Semaglutide mimics a natural gut hormone that regulates appetite and food intake by acting on areas of the brain involved in hunger control.

In the landmark STEP 1 clinical trial, participants using semaglutide 2.4mg weekly achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. These results demonstrated significantly greater weight loss than previously available pharmacological interventions, leading to Wegovy's approval across multiple regulatory jurisdictions including the UK.

The medication works through three primary mechanisms: slowing gastric emptying to increase feelings of fullness, reducing appetite signals in the hypothalamus, and improving glycaemic control [2]. Patients typically report reduced hunger and earlier satiety during meals, making it easier to adhere to reduced-calorie dietary patterns essential for sustained weight management.

Wegovy Dosing Schedule and Administration

Wegovy follows a structured dose-escalation protocol designed to minimise gastrointestinal side effects whilst optimising therapeutic efficacy. Treatment begins with 0.25mg once weekly for four weeks, then increases monthly through 0.5mg, 1mg, and 1.7mg doses before reaching the maintenance dose of 2.4mg weekly [2].

Each pre-filled pen is administered subcutaneously (under the skin) in the abdomen, thigh, or upper arm. The injection site should be rotated weekly to reduce localised reactions. Wegovy can be taken at any time of day, with or without meals, though maintaining a consistent weekly schedule optimises hormone level stability.

The gradual titration schedule typically spans 16-20 weeks before reaching full therapeutic dosing. This approach allows your digestive system to adapt to semaglutide's effects on gastric emptying, significantly reducing the incidence and severity of nausea reported in clinical trials [1]. Your UK prescriber will monitor your progress and may adjust the escalation timeline based on your individual tolerance and response.

What to Expect During Treatment

Most patients begin noticing reduced appetite within the first two weeks of treatment, though significant weight loss typically becomes apparent after reaching higher doses. Clinical trial data shows the greatest weight reduction occurs between weeks 20 and 60 of continuous treatment [1]. Consistency with weekly injections and adherence to lifestyle modifications including dietary changes and increased physical activity remain essential for optimal outcomes.

Wegovy vs Mounjaro: Comparing GLP-1 Treatments

Both Wegovy (semaglutide) and Mounjaro (tirzepatide) are injectable medications licensed in the UK for weight management, but they differ in their receptor mechanisms and clinical efficacy profiles. Wegovy activates GLP-1 receptors exclusively, whilst Mounjaro is a dual GIP/GLP-1 receptor agonist, targeting two complementary metabolic pathways [3].

Head-to-head trial data from the SURPASS-2 study demonstrated that tirzepatide produced greater average weight loss than semaglutide 1mg weekly in patients with type 2 diabetes, with the highest tirzepatide dose (15mg) achieving up to 11.2kg greater reduction [3]. However, both medications show substantial efficacy for weight management when used at their respective licensed doses for obesity treatment.

Treatment selection depends on multiple factors including your medical history, previous medication responses, cost considerations, and prescriber assessment. At Cured Pharmacy, our UK clinical team evaluates your individual circumstances during the free online consultation to recommend the most appropriate option. Some patients may trial one medication before switching to another based on tolerability or efficacy response.

Other Weight Loss Treatment Options

Beyond GLP-1 receptor agonists, Cured Pharmacy offers alternative weight management medications including Saxenda (liraglutide), a daily injectable GLP-1 treatment, and oral options such as Orlistat, which reduces dietary fat absorption. Mysimba combines naltrexone and bupropion to target appetite regulation through different neurological pathways. Your prescriber will discuss which treatment aligns with your weight loss goals, lifestyle preferences, and clinical suitability during your consultation.

Common Side Effects and Management Strategies

The most frequently reported side effects of Wegovy involve the gastrointestinal system, reflecting semaglutide's mechanism of slowing gastric emptying. In the STEP trials, nausea occurred in approximately 44% of participants, typically mild to moderate in severity and diminishing over time [1]. Other common effects include diarrhoea, constipation, vomiting, and abdominal discomfort.

Most gastrointestinal symptoms peak during dose escalation phases and resolve within several weeks as your body adapts. Practical management strategies include eating smaller, more frequent meals, avoiding high-fat foods that delay digestion further, staying well-hydrated, and taking the injection on an empty stomach if nausea occurs post-meal [2].

Serious adverse effects are uncommon but require immediate medical attention. These include signs of pancreatitis (severe persistent abdominal pain radiating to the back), gallbladder problems, significant changes in vision, or symptoms of thyroid tumours (lump in neck, hoarseness, difficulty swallowing). Your prescriber will assess your risk factors for these conditions before prescribing Wegovy, and you should report any concerning symptoms promptly during treatment.

Who Can Use Wegovy: Eligibility Criteria

Wegovy is licensed in the UK for adults with an initial BMI of 30 kg/m² or greater (classified as obese), or 27 kg/m² or greater (overweight) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea [2]. Clinical assessment by a UK prescriber is mandatory before treatment initiation to verify eligibility and screen for contraindications.

Wegovy is contraindicated in individuals with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), as GLP-1 receptor agonists caused thyroid C-cell tumours in rodent studies [1]. It should not be used during pregnancy or breastfeeding, and women of childbearing potential should use effective contraception during treatment and for two months after discontinuation.

Additional contraindications include severe gastrointestinal disease, history of pancreatitis, diabetic retinopathy complications, and severe renal impairment. Your Cured Pharmacy prescriber will review your complete medical history, current medications, and any previous adverse reactions to GLP-1 treatments during your online consultation to ensure Wegovy is clinically appropriate and safe for your individual circumstances.

Pre-Treatment Health Assessment

Before starting Wegovy, your prescriber may recommend baseline measurements including weight, BMI calculation, blood pressure, and in some cases blood tests to assess kidney function, liver enzymes, and HbA1c if you have diabetes. These baseline values provide important reference points for monitoring treatment response and identifying any emerging concerns during ongoing therapy. Regular follow-up consultations allow dose adjustments and ensure you're progressing safely towards your weight management goals.

Private Prescription Process at Cured Pharmacy

Accessing Wegovy through Cured Pharmacy begins with our free online clinical consultation, which takes under three minutes to complete. You'll answer questions about your medical history, current medications, weight management goals, and any previous treatments you've tried. This information is reviewed by our UK-registered prescribers who assess suitability according to MHRA licensing criteria and NICE guidance [4].

If clinically appropriate, your prescriber will issue a private prescription for Wegovy at the starting dose. Our pharmacy team, supervised by superintendent pharmacist Tarun Kumar (GPhC 2233073), dispenses genuine UK-licensed medication in discreet packaging. We offer next-day delivery across the UK, with tracking provided for your peace of mind. Transparent pricing means you'll see the exact cost before completing your consultation—no hidden fees or unexpected charges.

Ongoing prescription refills follow the same streamlined process. As you progress through the dose escalation schedule, simply complete a brief follow-up consultation confirming your current dose tolerance and any side effects. Our prescribers review your progress and authorise the next dose tier when clinically appropriate. This integrated prescription and dispensing service eliminates the need for separate GP appointments, making private weight management treatment accessible and convenient whilst maintaining full clinical oversight.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). Retrieved from https://www.medicines.org.uk/emc/product/13799/smpc [accessed 13 August 2026]
3. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., Brown, K. D., SURPASS-2 Investigators. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. Retrieved from https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to treatment, dietary modifications, and lifestyle changes. Wegovy is a prescription-only medicine licensed for chronic weight management and should only be used under medical supervision.